Searched for
NOVO NORDISK WEGOVY
Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetesBritain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...- School Assembly News Headlines, August 6, 2026: Top national, international, business, sports updates and thought of the daySchool Assembly News Headlines: The Lok Sabha in India has successfully passed a significant bill aimed at modernizing banking evidence law...
- Global Market: European shares climb as earnings, US-Iran diplomacy lift sentimentEuropean stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased ...
- Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipelineNovo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...
- Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cutsPfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The co...
- GLP-1 demand stirs up hunger for obesity care talentDemand for nutrition professionals is rapidly rising across India. Hospitals and digital health platforms are hiring more dietitians and ed...
- Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug adsNovo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drugNovo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...
- Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatmentEmcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treati...
- Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGATakeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individua...
- US companies face rise in cyber attacksCompanies worldwide are experiencing a rise in AI-driven cyberattacks and ransomware incidents. Fairlife, a Coca-Cola-owned dairy company, ...
- Novo Nordisk's obesity drug Wegovy wins India approval to fight silent fatty liver killerIndia's drug regulator approved Novo Nordisk's Wegovy for MASH treatment. This drug targets a serious progressive form of fatty liver disea...
- Novo Nordisk launches once-weekly basal insulin 'Awiqli' in India as diabetes rates increaseNovo Nordisk has launched Awiqli, a new weekly basal insulin injection, in India. This innovative drug offers a once-weekly alternative to ...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- Wegovy pill explained: Pricing, doses, and where to get Novo Nordisk's oral GLP-1 weight loss drugWegovy pill: Novo Nordisk is launching the first oral GLP-1 pill for weight loss, offering a more affordable alternative to injections. The...
- Hims stock tanks over 20% after Wegovy deal collapse — why Novo Nordisk’s breakup over weight loss drugs is shaking up Wall StreetHims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. Th...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
- Biggest pharma blockbuster? All about Wegovy, Novo Nordisk's obesity drug, that cuts risk of heart attacks and strokes by 20%In a groundbreaking achievement, Novo Nordisk's obesity medication Wegovy has not only demonstrated its efficacy in substantial weight loss...
Load More
